ENTITY
Bristol Myers Squibb Co

Bristol Myers Squibb Co (BMY US)

230
Analysis
Health Care • United States
Bristol-Myers Squibb Company is a global biopharmaceutical company. The Company develops, licenses, manufactures, markets, and sells pharmaceutical and nutritional products. Bristol-Myers Squibb products and experimental therapies address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection, and psychiatric disorders.
more
bearish•S&P 500 INDEX
•31 Mar 2020 21:34

U.S. Equities: Test Of The Lows Coming?

Now that the initial/primary low has been established and with the S&P 500 roughly 20% off the lows, we believe it is time to map out potential...

Logo
481 Views
Share
bullish•S&P 500 INDEX
•12 Dec 2019 21:11

U. S. Equity Strategy: Small-Caps Closing the Gap

Major averages in the US (S&P 500, Dow, Russell 2000) and Europe (STOXX 600 & 50) each had throwbacks to their prior breakout levels last...

Logo
518 Views
Share
bullish•Alphamab Co Ltd
•28 Nov 2019 16:23

Alphamab Oncology IPO Initiation: Clear Diagnosis

Alphamab Co Ltd (1728643D CH) is a pre-revenue biotech company with a focus on research and development, manufacturing and commercialisation of...

Logo
582 Views
Share
bullish•Allergan Plc
•31 Aug 2019 08:47

Allergan Plc Acquisition by AbbVie Inc. – A Botox Deal with Some Wrinkles

On June 25, 2019, Abbvie Inc (ABBV US) announced its acquisition of Botox-maker Allergan Plc (AGN US) in a $63 billion cash and stock deal in which...

Logo
788 Views
Share
•12 Jun 2019 10:05

Immuno-Oncology Drugs in Adjuvant Lung: The Next Frontier in Strengthening Moats

The potential for Merck and Roche looks underappreciated.Innovation in immuno-oncology drugs has supported the moats for Merck & Co Inc. (MRK...

Share
x